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Background: Same day discharge after elective PCI is rare in the Unites States, partly
due to concerns over access site complications associated with transfemoral intervention
(TFI). The timing of access site bleeding after TFI in the modern era of PCI is unclear.
Methods: 1525 consecutive patients undergoing elective PCI between January 2008 to May
2012 at a community hospital, were prospectively followed throughout their hospitalization.
Patients undergoing radial procedures, on warfarin, and those receiving intra-aortic balloon
pump were excluded. Early access site bleed was defined as any bleeding that occurred
within 6 hours of completion of procedure, and late bleeds were defined as those occurring
after 6 hours. Demographic , procedural and laboratory parameters were compared between
patients who had bleeding versus those who did not (Table 1).
Results: 78 patients (5.1%) developed access site bleeding. 70 events (90%) occurred less
than 6 hours after the procedure and 8 events (10%), after 6 hours. Median time to
bleeding was 30 minutes in the early group, and 7.75 hours in the late group, and 1
hour for the entire cohort. Results of univariate analysis are shown in Table 1, with female
gender and glycoprotein 2b/3a inhibitors identified as significant predictors of access site
bleeding. Multivariate analysis did not identify any predictors of late bleeds.
Conclusions: Majority of the access site bleeding events after transfemoral PCI occur within
six hours after the index procedure. Although these findings have favorable implications on
same day discharge strategy, a larger study to identify predictors of late bleeds is needed.
Access site bleed (N) No access site bleed (N) P-value
Female Gender 49/78 (62.8%) 514/1447 (35.5%) 0.001
Diabetes 27/78 (34.6%) 536/1447 (37.04%) 0.38
Hypertension 63/78 (80.76%) 1133/1447 (78.29%) 0.36
CABG 10/78 (12.82%) 228/1447 (15.75%) 0.30
GP2b3a 14/78 (17.94%) 157/144 (10.9%) 0.046
Bivalirudin 40/78 (51.28%) 861/1447 (59.5%) 0.47
Age 67.8  11.9 66.2  12.4 0.265
Height (Inches) 67.2  4.3 67.1  4.3 0.929
Weight (lbs) 192.1  42.4 193.2  46.8 0.826
Baseline Hemoglobin 13.3  1.9 13.3  1.9 0.691
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Background: Stroke after left cardiac catheterization is infrequent but it represents the
most debilitating complication from the patient perspective. Whereas the overall rate of
adverse events declined over the last decades, the incidence of periprocedural stroke has
remained unchanged. Ischemic stroke represents a high majority of symptomatic strokes
and the potential mechanisms underlying these events include thrombus or air emboliza-
tion, iatrogenic arterial dissection, hypotension and embolization debris of atheroma from
the aortic wall. Given the devastating consequence, we sought to identify incidence,
in-hospital outcomes and all modifiable and no modifiable risks factors of this adverse
event in a high volume center.
Methods: Our retrospective study included all patients experiencing periprocedural
ischemic stroke among 24500 patients who underwent left cardiac catheterization
between January 2003 and October 2010. The stroke group were compared with a case
group control of 500 individuals randomized from the initial source population.
Results: Ischemic cardiovascular events occurred in 46 patients (0.19% of procedures)
and included transient ischemic attack (TIA) in 16 cases and stroke in 30 cases. Hospital
stay was significantly prolonged (12.4 vs 8.2 days p0.001) and the in-hospital mortality
was higher (8.7% vs 0.6% p0.001) in stroke group. On multivariate analysis, diabetes
mellitus (adjusted odds ratio ¬(OR) 3,6; 95% confidence interval (CI) 1,7 to 7,7;
p0,001); chronic renal dysfunction (OR 2,4, 95% CI 1,1-5,4; p0,001), known
cerebrovascular disease (OR 7,3, 95% CI 3-17,8; p0,001) and recent congestive heart
failure (OR 2,6, 95% CI 1,1-6; p0,001) were independent predictors for stroke. The
independent modifiable predictive factors were represented by left ventricular angiogra-
phy (OR 5,6, 95% CI 2,2-13,8; p0,001), emergent cardiac catheterization (OR 4,5, 95%
CI 1,8-11,2; p0,01) and low operator volume (OR 2,7, 95% CI 1,3-3,8; p0, 01).
Conclusions: A really careful procedural planning taking account patients, procedural
risk factors and operator experience might still actually decrease the incidence of this
devastating complication.
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Background: The long-term clinical outcome of bulky covered stents in the percutaneous
treatment of diseased saphenous vein graft (SVG) has been disappointing. However, the single
self-expanding polytetrafluoroethylene (PTFE)-covered Symbiot stent with a unique profile,
has not been evaluated and may present advantages that translate into superior long-term
clinical outcomes. This study evaluated the safety, effectiveness and clinical outcome of the
SymbiotTM covered stent system (Boston Scientific, Natick, Mass.) and FilterWireTM EX
(Boston Scientific, Natick, Mass.) versus bare metal stents (BMS) in SVG intervention.
Methods: Between January 2003 and August 2005, 90 patients with degenerative SVG
lesions were prospectively randomized at 6 study sites to Symbiot implantation (n30),
BMS with FilterWire as embolic protection device (EPD, n30), or BMS without EPD
(control group, n30). The primary endpoint was reduction in peri-procedural cardiac
enzyme rise. The major secondary endpoints were in-hospital, 6 month and long-term
target vessel failure (TVF) rates, defined as the cumulative of death, myocardial infarction
and clinically-driven target lesion revascularization.
Results: There was no significant reduction in median [IQR] post-procedural troponin-I
rise in the Symbiot group compared to the FilterWire or the Control group (0.08 [0-1.40]
g/l; 0.06 [0-0.28] g/l; and 0.04 [0-0.31] g/l, p0.58). At 7.4  1.3 (mean  SD)
years of follow-up (Table), there were numerically less deaths in the Symbiot group,
although this did not reach statistical significance (p0.20). There was no significant
difference in TVF-free survival between the treatment groups (p0.98).
Clinical Events at Longest Available Clinical Follow-Up
Values are mean SD and event rates are Kalpan-Meier estimates (number
of events (%))
Symbiot
Group
FilterWire
group
Control
Group
p Value(n  30) (n  30) (n  30)
Long-Term Follow-Up
(years)
7.3  1.6 7.6  0.9 7.4  1.6 0.68
Death, all cause
In-hospital 1 (3) 1 (3) - 0.60
6 Months 3 (10) 2 (7) 1 (3) 0.58
Long -Term 6 (20) 13 (43) 11 (37) 0.20
Myocardial infarction
In-hospital 2 (7) 1 (3) 1 (3) 0.76
6 Months 2 (7) 2 (7) 2 (7) 1.00
Long -Term 7 (23) 5 (17) 7 (23) 0.69
Target lesion
revascularization
In-hospital 1 (3) - - 0.37
6 Months 3 (10) 2 (7) 1 (3) 0.59
Long -Term 8 (27) 5 (17) 10 (33) 0.32
Target vessel failure
In-hospital 3 (10) 1 (3) 1 (3) 0.42
6 Months 6 (20) 4 (13) 3 (10) 0.33
Long -Term 17 (57) 17 (57) 18 (60) 0.98
Values are mean  SD and event rates are Kaplan-Meier estimates (number of events (%))
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Conclusions: The long-term prognosis after percutaneous treatment of diseased SVGs is
poor. This study failed to show a procedural or long-term clinical advantage for the
Symbiot PTFE-covered stent in the treatment of degenerated SVG.
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Background: Acute myocardial infarction (MI) and cardiogenic shock are known to
predict bleeding in patients undergoing percutaneous coronary intervention (PCI).
However, the association between the severity of clinical presentation and bleeding after
PCI has not been well defined. This study aims to compare the impact of the spectrum of
clinical presentation on PCI-related bleeding.
Methods: The study included a cohort of 22686 consecutive patients who underwent
PCI. Patients were categorized according to their clinical presentation: stable angina
pectoris (SAP, n6232), unstable angina pectoris (UAP, n4705), non ST-segment
elevation MI (NSTEMI, n8335), ST-segment elevation MI (STEMI, n2562) and
cardiogenic shock (CGS, n852).
Results: The mean left ventricular ejection fraction (LVEF) of patients decrease from
SAP to CGS.(Table) There was greater use of intra-aortic balloon pump (IABP) and
glycoprotein inhibitors with increasing severity of clinical presentation. The incidence of
major bleeding, defined as gastrointestinal bleeding, hematocrit drop and major hema-
toma, increased with severity of clinical presentation, from 0.7% in SAP to 15.4% in
CGS. The need for blood product transfusion followed a similar increase across the
clinical spectrum, lowest in SAP (2.1%) and highest in CGS (27.4%). The in-hospital
mortality rate corresponded with the severity of clinical presentation.
Table: Patient and procedural characteristics and in-hospital bleeding and
mortality
SAP
(n6232)
UAP
(n4705)
NSTEMI
(n8335)
STEMI
(n2562)
CGS
(n852) P value
Age, years 65.7 
11.3
64.4 
11.9
63.9 
58.9
62.2 
13.7
64.7 
14.2
0.001
LVEF, % 51  14 50  15 48  14 42  14 34  14 0.001
Intra-aortic balloon pump, % 1.0 1.9 2.7 11.9 57.3 0.001
Glycoprotein receptor
inhibitors, %
8.8 10 19.7 21.1 26.7 0.001
Major bleeding, % 0.7 1.1 2.0 4.3 15.4 0.001
Gastrointestinal bleeding, % 0.3 0.4 0.8 0.8 5.8 0.001
Hematocrit drop, % 0.6 0.9 1.5 4.0 13.1 0.001
Major hematoma, % 0.2 0.2 0.3 0.7 1.5 0.001
Need for blood transfusion,
%
2.1 2.8 4.3 7.8 27.4 0.001
In-hospital death, % 0.2 0.4 0.9 2.3 22.5 0.001
In-hospital cardiac death, % 0.1 0.3 0.6 1.9 18.7 0.001
Conclusions: In patients undergoing PCI, the worsening severity of clinical presentation
corresponds to an increase in incidence of in-hospital bleeding. This may be due to the
increased use of more aggressive adjunct pharmacotherapy and IABP.
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Background: In acute coronary syndromes (ACS), upstream anticoagulation such as
unfractionated heparin (UFH) or low molecular weight heparin (LMWH), is frequently
administered prior to percutaneous coronary intervention (PCI) to decrease ischemic
complications. This study aims to compare the in-hospital bleeding complications of
patients who received upstream UFH versus upstream LMWH versus none.
Methods: The study included 6772 consecutive patients presenting with ACS who
underwent PCI. Patients were categorized into upstream therapies of UFH (n881),
LMWH (n2554), and none (n3337). Patient and procedural characteristics and
incidences of in-hospital bleeding complications and mortality were compared among
groups.
Results: The mean age was 63.4 years overall. Cardiogenic shock was present in 14.8%, 8%,
and 3.2% (p 0.01) of patients given upstream therapies of UFH, LMWH and none,
respectively. Similarly, the use of IABP was 16.9%, 11.6% and 6.2% (p0.001) respectively.
Glycoprotein receptor inhibitor use was 24.3%, 14% and 6.4% (p0.001) respectively. During
PCI, heparin use was 27.5%, 17.7% and 11.3% (p0.001). Mean dosages given were 1361U,
2126U, and 2689U (p 0.001). Conversely, bivalirudin use was 50.2%, 70% and 86.8% (p
0.001) in upstream UFH, LMWH and none, respectively. In-hospital major bleeding
(defined as gastrointestinal bleeding, significant hematocrit drop and major hematoma) and
mortality rates were highest in patients given upstream UFH, followed by LMWH and none.
(Table)
Table: In-hospital bleeding complications and mortality
Upstream
unfractionated
heparin
(n881)
Upstream low
molecular
weight
heparin
(n2552)
No upstream
anticoagulation
(n3334) P-value
Major bleeding, % 5.3 4.6 2.4 0.001
Gastrointestinal
bleeding, %
1.5 1.1 0.8 0.001
Hematocrit drop, % 4.3 3.9 2.0 0.001
Major hematoma, % 0.9 0.5 0.3 0.001
Need for blood
transfusion, %
10.0 8.2 5.2 0.001
Death, % 4.9 3.3 2.5 0.001
Cardiac death, % 3.7 2.5 2.1 0.019
Conclusions: ACS patients given upstream UFH were most ill on presentation, they
received a higher amount of potent antithrombotic therapies during PCI as compared to
LMWH and no upstream anticoagulation. The additive contributions of antithrombotic
therapy, both upstream and during PCI, may account for the higher incidence of bleeding
in patients receiving upstream UFH and LMWH compared to no upstream anticoagula-
tion.
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Background: Percutaneous coronary intervention (PCI) of saphenous vein grafts (SVG)
is associated with a high risk of complications due to distal embolization and no-reflow.
Although distal protection devices are routinely used, periprocedural ischemic complica-
tions still occur in up to 10% of SVG interventions. Intracoronary vasodilating drugs are
effective in treating no-reflow and may have a salutary effect if administered prior to PCI.
The goal of this study was to assess the efficacy of prophylactic intracoronary (IC)
nicardipine in conjunction with distal protection devices during SVG intervention.
Methods: The clinical outcomes at 30 days were assessed in 163 consecutive patients
undergoing PCI of SVG with use of distal protection devices. In Group I, 60 patients
underwent PCI with a distal protection device alone (no pretreatment nicardipine). In
Group II, 103 patients underwent PCI with both distal protection device and prophylactic
IC nicardipine (initial 200 mcg bolus before filter placement and supplemental 100 mcg
doses before balloon and stent inflations). The incidence of 30 day MACE (death, MI,
CABG, or repeat PCI) was compared in the two groups. Periprocedural MI was defined
as elevated cardiac markers  3 times the upper normal limit.
Results: Group I and Group II had similar baseline patient demographics including age
(718 vs 7210 years), diabetes (47 vs 44%), and ACS (58 vs 70%); all pns. SVG age
was also similar in the two groups (13.1 6.3 vs 13.4 5.6 years, pns). Group II had
longer lesion length requiring longer total stent length (22.7  11.6 vs 28.2  16.8 mm,
p 0.026) and were more likely to have ACC/AHA Class C lesions (13 vs 30%, p
0.015). At 30 days, MACE occurred in 10.0% of Group I and in 1.0% of Group II (p
0.01). Mortality was 3.3% in Group I and 0 in Group II (p 0.13). Incidence of MI was
10.0 vs 1.0% (p 0.01). Within 30 days, there were no CABG, repeat PCI, or stent
thromboses in either group.
Conclusions: Prophylactic use of intracoronary nicardipine prior to SVG intervention
has synergistic effects when combined with distal protection devices. Dual protection with
drugs and devices is associated with better outcomes than with distal protection devices
alone.
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